PTCT · PTC Therapeutics, Inc.
$60.59
-3.89% last session
End-of-day data · close of 2026-10-23
Market cap
$5B
Enterprise value
$6B
Trailing P/E
—
Forward P/E
25.6
Dividend yield
0.0%
Beta
0.49
Avg volume
1M
Employees
1K
Daily Change %
-3.89%
5 Days Change
6.41%
10 Days Change
5.21%
30 Days Change
1.12%
60 Days Change
-11.29%
Month to Day Change
-1.70%
Year to Day Change
-17.01%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PTCT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-08
Latest call per bank · past 12 months
RBC Capital
Sector Perform$75.00
+23.8% vs priceBarclays
Overweight$122
+101.4% vs priceWells Fargo
Overweight$109
+79.9% vs priceMorgan Stanley
Overweight$104
+71.6% vs priceJefferies
Buy$85.00
+40.3% vs priceBank of America
Buy$93.00
+53.5% vs priceCitigroup
Neutral$75.00
+23.8% vs priceGoldman Sachs
Sell$50.00
-17.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | RBC Capital | Maintains | Sector Perform | $85.00 → $75.00 |
| 2026-09-22 | Cantor Fitzgerald | Maintains | Overweight | $130 → $137 |
| 2026-08-14 | Barclays | Maintains | Overweight | $120 → $122 |
| 2026-08-13 | Wells Fargo | Maintains | Overweight | $106 → $109 |
| 2026-07-31 | Morgan Stanley | Maintains | Overweight | $93.00 → $104 |
| 2026-07-31 | Wells Fargo | Maintains | Overweight | $93.00 → $106 |
| 2026-07-20 | Wells Fargo | Maintains | Overweight | $95.00 → $93.00 |
| 2026-07-16 | Cantor Fitzgerald | Maintains | Overweight | $124 → $130 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 8.7% below the 50-day MA ($66.38).
- bearish: Price vs 200-day MA: Trading 14.7% below the 200-day MA ($71.04).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.24) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($59.24).
PTCT Price Chart
Loading chart for PTCT…
Fundamentals
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.